

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LIFESCAN, INC., SENSEONICS HOLDINGS, INC., and
ASCENSIA DIABETES CARE HOLDINGS AG,
Petitioners,

v.

CELLSPIN SOFT, INC.,
Patent Owner.

IPR2025-00102 (Patent 11,234,121 B2)
IPR2025-00103 (Patent 9,900,766 B2)
IPR2025-00104 (Patent 8,904,030 B2)¹

Before GREGG I. ANDERSON, CYNTHIA M. HARDMAN, and
MICHAEL A. VALEK, *Administrative Patent Judges*.

HARDMAN, *Administrative Patent Judge*.

TERMINATION
Due to Settlement After Institution of Trial
35 U.S.C. § 317; 37 C.F.R. § 42.74

¹ This Order addresses issues common to the identified proceedings. The parties are not authorized to use this caption without express authorization.

IPR2025-00102 (Patent 11,234,121 B2)

IPR2025-00103 (Patent 9,900,766 B2)

IPR2025-00104 (Patent 8,904,030 B2)

On June 25, 2026, pursuant to 35 U.S.C. § 317(a), the parties filed a Joint Motion to Terminate in the above-captioned proceedings. *See* Paper 28.² Additionally, pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), the parties filed copies of a confidential Settlement Agreement between (i) Patent Owner and Senseonics Holdings, Inc. and Ascensia Diabetes Care Holdings AG (Exhibit 1037); and (ii) Patent Owner and Lifescan, Inc. (Exhibit 1038). The parties also filed a Joint Motion to Treat as Confidential (Paper 28), requesting that the agreements be treated as business confidential information and be kept separate from the patent files.

The Board has instituted review in these proceedings, but has not yet issued any final written decision. The parties indicate that they have reached a settlement disposing of these proceedings and “all related proceedings” (including the related district court litigation). Paper 28, 1. The parties represent that “there are no other collateral agreements or understandings, oral or written, between the Parties made in connection with, or in contemplation of, the termination of th[ese] proceeding[s].” *Id.*

Under these circumstances, we determine that it is appropriate to terminate these proceedings without rendering final written decisions, and to treat the Settlement Agreements as business confidential information, to be kept separate from the patent files. 37 C.F.R. § 42.74.

² We cite papers and exhibits filed in IPR2025-00102. Substantively identical papers and exhibits were filed in the other captioned proceedings.

IPR2025-00102 (Patent 11,234,121 B2)

IPR2025-00103 (Patent 9,900,766 B2)

IPR2025-00104 (Patent 8,904,030 B2)

ORDER

In consideration of the foregoing, it is hereby:

ORDERED that the parties' request that the Settlement Agreements (Exhibits 1037 and 1038) be treated as business confidential information, to be kept separate from the patent files, is *granted*;

FURTHER ORDERED that the Joint Motion to Terminate is *granted*; and

FURTHER ORDERED that the above-captioned proceedings are terminated.

IPR2025-00102 (Patent 11,234,121 B2)

IPR2025-00103 (Patent 9,900,766 B2)

IPR2025-00104 (Patent 8,904,030 B2)

For PETITIONERS:

Charles McMahon

Thomas DaMario

BENESCH FRIEDLANDER COPLAN & ARONOFF LLP

cmcmahon@beneschlaw.com

tdamario@beneschlaw.com

Joseph Hynds

Michael Battaglia

ROTHWELL, FIGG, ERNST & MANBECK, P.C.

jhynds@rfem.com

mbattaglia@rfem.com

For PATENT OWNER:

Rene Vazquez

Michael Fuller

SINERGIA TECH. LAW GROUP, PLLC

rvazquez@singergialaw.com

sfuller@ghiplaw.com